Supportive Care in Cancer

, Volume 17, Issue 6, pp 745–748

Futile medication use in terminally ill cancer patients

  • Rachel P. Riechelmann
  • Monika K. Krzyzanowska
  • Camilla Zimmermann
Short Communication

Abstract

Background

Cancer patients usually take many medications. The proportion of patients with advanced cancer who are taking futile drugs is unknown.

Materials and methods

We retrospectively reviewed the charts of all consecutive ambulatory patients with advanced cancer and who were receiving supportive care exclusively at palliative care clinics, Princess Margaret Hospital, to gather information on futile medications used by them. Futile medications were defined as unnecessary (when no short-term benefit to patients with respect to survival, quality of life, or symptom control was anticipated) or duplicate (two or more drugs from the same pharmacological class). Summary statistics were used to describe the results.

Results

From November 2005 to July 2006, 82 (22%) of 372 patients were taking at least one futile medication before consultation; after initial consultation, this proportion dropped to 20% (78): 70 patients were taking unnecessary medications, while eight were on duplicate medications. The most frequent unnecessary medications used by patients were statins (56%). The most common duplicate medication involved the use of two different benzodiazepines (seven patients).

Conclusion

About one fifth of cancer outpatients at the end of life take futile medications, most commonly statins. Prospective and population-based studies are warranted to further evaluate the magnitude and consequences of futile medication use in oncology.

Keywords

Cancer Drug therapy Medical futility 

References

  1. 1.
    Jecker NS, Pearlman RA (1992) Medical futility. Who decides? Arch Intern Med 152:1140–1144 doi:10.1001/archinte.152.6.1140 PubMedCrossRefGoogle Scholar
  2. 2.
    Kite S, Wilkinson S (2002) Beyond futility: to what extent is the concept of futility useful in clinical decision-making about CPR? Lancet Oncol 3:638–642 doi:10.1016/S1470-2045(02)00878-1 PubMedCrossRefGoogle Scholar
  3. 3.
    Kasman DL (2004) When is medical treatment futile? A guide for students, residents, and physicians. J Gen Intern Med 19:1053–1056 doi:10.1111/j.1525-1497.2004.40134.x PubMedCrossRefGoogle Scholar
  4. 4.
    Frick S, Uehlinger DE, Zuercher Zenklusen RM (2003) Medical futility: predicting outcome of intensive care unit patients by nurses and doctors—a prospective comparative study. Crit Care Med 31:456–461 doi:10.1097/01.CCM.0000049945.69373.7C PubMedCrossRefGoogle Scholar
  5. 5.
    Curtis JR, Patrick DL, Caldwell ES, Collier AC (2000) The attitudes of patients with advanced AIDS toward use of the medical futility rationale in decisions to forego mechanical ventilation. Arch Intern Med 160:1597–1601 doi:10.1001/archinte.160.11.1597 PubMedCrossRefGoogle Scholar
  6. 6.
    Clark PA (2002) Medical futility in pediatrics: is it time for a public policy? J Public Health Policy 23:66–89 doi:10.2307/3343119 PubMedCrossRefGoogle Scholar
  7. 7.
    Cantor MD, Braddock CH 3rd, Derse AR et al (2003) Do-not-resuscitate orders and medical futility. Arch Intern Med 163:2689–2694 doi:10.1001/archinte.163.22.2689 PubMedCrossRefGoogle Scholar
  8. 8.
    Burt RA (2002) The medical futility debate: patient choice, physician obligation, and end-of-life care. J Palliat Med 5:249–254 doi:10.1089/109662102753641223 PubMedCrossRefGoogle Scholar
  9. 9.
    Escalante CP, Martin CG, Elting LS, Rubenstein EB (1997) Medical futility and appropriate medical care in patients whose death is thought to be imminent. Support Care Cancer 5:274–280 doi:10.1007/s005200050074 PubMedCrossRefGoogle Scholar
  10. 10.
    von Gruenigen VE, Daly BJ (2005) Futility: clinical decisions at the end-of-life in women with ovarian cancer. Gynecol Oncol 97:638–644 doi:10.1016/j.ygyno.2005.01.031 CrossRefGoogle Scholar
  11. 11.
    Honegger HP (1991) Avoiding futility: assessment of cancer patients in intensive care units. Ann Oncol 2:530–531PubMedGoogle Scholar
  12. 12.
    Nicholson A, Andrew I, Etherington R, et al (2001) Futile and inappropriate prescribing: an assessment of the issue in a series of patients admitted to a palliative care unit. Available at http://www.pharmj.com/IJPP/bpc2001/ijpp_bpc2001_r72.pdf
  13. 13.
    Riechelmann RP, Krzyzanowska MK, O'Carroll A, Zimmermann C (2007) Symptom and medication profiles among cancer patients attending a palliative care clinic. Support Care Cancer 15:1407–1412 doi:10.1007/s00520-007-0253-8 PubMedCrossRefGoogle Scholar
  14. 14.
    Riechelmann RP, Zimmermann C, Chin S et al (2008) Potential drug interactions in cancer patients receiving palliative care exclusively. J Pain Symptom Manage 08(35):535–543 doi:10.1016/j.jpainsymman.2007.06.009 CrossRefGoogle Scholar
  15. 15.
    Zimmermann C, Seccareccia D, Clarke A et al (2006) Bringing palliative care to a Canadian cancer center: the palliative care program at Princess Margaret Hospital. Support Care Cancer 14:982–987 doi:10.1007/s00520-006-0093-y PubMedCrossRefGoogle Scholar
  16. 16.
    Zimmermann C, Walsh A, Gagliese L et al (2007) Determinants of referral of cancer patients to specialized palliative care. Psychooncology 16:S57Google Scholar
  17. 17.
    Currow DC, Stevenson JP, Abernethy AP et al (2007) Prescribing in palliative care as death approaches. J Am Geriatr Soc 55:590–595 doi:10.1111/j.1532-5415.2007.01124.x PubMedCrossRefGoogle Scholar
  18. 18.
    Corcoran ME (1997) Polypharmacy in the older patient with cancer. Cancer Control 4:419–428PubMedGoogle Scholar
  19. 19.
    Riechelmann RP, Tannock IF, Wang L et al (2007) Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst 99:592–600 doi:10.1093/jnci/djk130 PubMedCrossRefGoogle Scholar
  20. 20.
    Bottorff MB (2006) Statin safety and drug interactions: clinical implications. Am J Cardiol 97:27C–31C doi:10.1016/j.amjcard.2005.12.007 PubMedCrossRefGoogle Scholar
  21. 21.
    Vollrath AM, Sinclair C, Hallenbeck J (2005) Discontinuing cardiovascular medications at the end of life: lipid-lowering agents. J Palliat Med 8:876–881 doi:10.1089/jpm.2005.8.876 PubMedCrossRefGoogle Scholar
  22. 22.
    Basu TK (1985) Drug–vitamin interaction. Int J Vitam Nutr Res Suppl 27:247–258PubMedGoogle Scholar
  23. 23.
    Glare P, Virik K, Jones M et al (2003) A systematic review of physicians’ survival predictions in terminally ill cancer patients. BMJ 327:195–198 doi:10.1136/bmj.327.7408.195 PubMedCrossRefGoogle Scholar
  24. 24.
    Samano ES, Goldenstein PT, Ribeiro Lde M et al (2004) Praying correlates with higher quality of life: results from a survey on complementary/alternative medicine use among a group of Brazilian cancer patients. Sao Paulo Med J 122:60–63 doi:10.1590/S1516-31802004000200005 PubMedCrossRefGoogle Scholar
  25. 25.
    Samano ES, Ribeiro LM, Campos AS et al (2005) Use of complementary and alternative medicine by Brazilian oncologists. Eur J Cancer Care (Engl) 14:143–148 doi:10.1111/j.1365-2354.2005.00524.x CrossRefGoogle Scholar
  26. 26.
    Back A (2006) Patient–physician communication in oncology: what does the evidence show? Oncology (Williston Park) 20:67–74 (discussion 77–78, 83)Google Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Rachel P. Riechelmann
    • 1
  • Monika K. Krzyzanowska
    • 2
  • Camilla Zimmermann
    • 3
  1. 1.Department of Internal MedicineFederal University of Sao PauloSão PauloBrazil
  2. 2.Department of Medical OncologyPrincess Margaret HospitalTorontoCanada
  3. 3.Psychosocial Oncology and Palliative CarePrincess Margaret HospitalTorontoCanada

Personalised recommendations